Literature DB >> 7975839

Kinetics of the vibriocidal antibody response to live oral cholera vaccines.

S S Wasserman1, G A Losonsky, F Noriega, C O Tacket, E Castañeda, M M Levine.   

Abstract

The best correlate of protection against cholera is the level of serum vibriocidal antibodies, which are primarily directed against the O antigen of Vibrio cholerae O1 and lyse V. cholerae in the presence of complement. We established the timing of peak vibriocidal antibody response using sera from safety/immunogenicity studies of live oral cholera vaccines CVD 103-HgR, CVD 103-HgR2 and CVD 110 among immunologically naive North Americans and Colombians. The serum reciprocal vibriocidal antibody titre was consistently higher 10 days postimmunization than on either day 7 or day 14. This study suggests that recent phase 2 studies of CVD 103-HgR may have underestimated the peak vibriocidal titre by collecting serum on days 7-8 rather than on day 10; future studies of live oral cholera vaccines should take these results into account to obtain the best measurement of peak immunological responses. Because of the rapid drop in vibriocidal antibody titres about 2 weeks after immunization, care must be exercised in comparing immunogenicity of different vaccine candidates, formulations, dosage levels and immunization schedules.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975839     DOI: 10.1016/0264-410x(94)90335-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi.

Authors:  Janet C Lindow; Kelly A Fimlaid; Janice Y Bunn; Beth D Kirkpatrick
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

2.  Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.

Authors:  Z Kossaczka; J Shiloach; V Johnson; D N Taylor; R A Finkelstein; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

3.  Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.

Authors:  J F Viret; D Favre; B Wegmüller; C Herzog; J U Que; S J Cryz; A B Lang
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

Review 4.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

5.  A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Authors:  R T Perry; C V Plowe; B Koumaré; F Bougoudogo; K L Kotloff; G A Losonsky; S S Wasserman; M M Levine
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

6.  Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.

Authors:  R K Gupta; D N Taylor; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

7.  Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia.

Authors:  Harriet Ng Ombe; Michelo Simuyandi; John Mwaba; Charlie Chaluma Luchen; Peter Alabi; Obvious Nchimunya Chilyabanyama; Cynthia Mubanga; Luiza Miyanda Hatyoka; Mutinta Muchimba; Samuel Bosomprah; Roma Chilengi; Geoffrey Kwenda; Caroline Cleopatra Chisenga
Journal:  PLoS One       Date:  2022-01-05       Impact factor: 3.240

8.  Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.

Authors:  Suman Kanungo; Anna Lena Lopez; Mohammad Ali; Byomkesh Manna; Deok Ryon Kim; Tanmay Mahapatra; Jan Holmgren; Mandeep S Dhingra; Thomas F Weirzba; G Balakrish Nair; Sujit K Bhattacharya; John D Clemens; Dipika Sur
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

9.  Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine.

Authors:  Oluwaseyi Adekunle; Alexandra Dretler; Robert C Kauffman; Alice Cho; Nadine Rouphael; Jens Wrammert
Journal:  PLoS Negl Trop Dis       Date:  2021-09-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.